In May 2023, Australia’s Therapeutic Goods Administration (TGA), the country’s FDA equivalent, moved to reschedule the use of psilocybin and MDMA for patients with treatment-resistant depression (TRD) and PTSD, respectively. That Summer, the downscheduling became a reality. Since then, certain psychiatrists (‘Authorised Prescribers’, in the country’s regulatory lingo) have been able to prescribe…
